Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Cancer Therapies02:49

Cancer Therapies

7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

130
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
130

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel Adipokine, FAM19A5, Inhibits Neointima Formation After Injury Through Sphingosine-1-Phosphate Receptor 2.

Circulation·2018
Same author

Liquid-Crystalline Dynamic Networks Doped with Gold Nanorods Showing Enhanced Photocontrol of Actuation.

Advanced materials (Deerfield Beach, Fla.)·2018
Same author

KCa(H<sub>2</sub> O)<sub>2</sub> [Fe<sup>III</sup> (CN)<sub>6</sub> ]⋅H<sub>2</sub> O Nanoparticles as an Antimicrobial Agent against Staphylococcus aureus.

Angewandte Chemie (International ed. in English)·2018
Same author

Warming deferentially altered multidimensional soil legacy induced by past land use history.

Scientific reports·2018
Same author

Advanced Modified Polyacrylonitrile Membrane with Enhanced Adsorption Property for Heavy Metal Ions.

Scientific reports·2018
Same author

Insulin-like growth factor 2 is a key mitogen driving liver repopulation in mice.

Cell death & disease·2018

Related Experiment Video

Updated: Jun 14, 2025

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer
06:19

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

10.0K

Immunotherapy for colorectal cancer.

Bing Yu1, Jian Kang1, Hong Lei1

  • 1Department of the Colorectal Anal Surgery, The Affiliated Taian City Centeral Hospital of Qingdao University, Tai'an, Shandong, China.

Frontiers in Immunology
|September 6, 2024
PubMed
Summary

Colorectal cancer immunotherapy offers a promising alternative to traditional treatments. This review highlights advancements in immune checkpoint inhibitors, cell therapy, tumor-infiltrating lymphocytes, and oncolytic viruses for better outcomes.

Keywords:
adoptive cell therapycolorectal cancerimmune checkpoint inhibitorsimmunotherapyoncolytic virus

More Related Videos

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.2K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

684

Related Experiment Videos

Last Updated: Jun 14, 2025

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer
06:19

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

10.0K
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.2K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

684

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Colorectal cancer is a leading cause of cancer-related deaths globally.
  • Traditional treatments like surgery, radiotherapy, and chemotherapy have limitations and significant side effects.
  • There is a critical need for more effective colorectal cancer therapies with improved safety profiles.

Purpose of the Study:

  • To review the latest advancements in immunotherapy for colorectal cancer.
  • To explore novel therapeutic strategies beyond conventional treatments.
  • To assess the potential of emerging immunotherapies in clinical settings.

Main Methods:

  • Literature review of recent studies on colorectal cancer immunotherapies.
  • Focus on immune checkpoint inhibitors, cell therapy, tumor-infiltrating lymphocytes, and oncolytic viruses.
  • Analysis of clinical trial data and current treatment applications.

Main Results:

  • Immunotherapy activates the immune system to target cancer cells, offering a new therapeutic avenue.
  • Several immunotherapies, including immune checkpoint inhibitors and cell therapies, show promising results in clinical trials.
  • Tumor-infiltrating lymphocytes and oncolytic viruses represent other rapidly developing areas of research.

Conclusions:

  • Immunotherapy is emerging as a powerful alternative for colorectal cancer treatment.
  • Advancements in immune-based strategies are improving patient outcomes and reducing treatment-related toxicities.
  • Further research and clinical application of these novel therapies are warranted.